Skip to main content
SpringerLink
Log in

The Busy Arena of Psoriasis Treatments: Improving the Clinician’s Ability to Make the Right Therapeutic Choice

  • Letter to the Editor
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

The Original Research Article was published on 30 March 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021. https://doi.org/10.1007/s40257-021-00598-4.

    Article  PubMed  Google Scholar 

  2. Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628–37.

    Article  CAS  Google Scholar 

  3. Reid C, Cordingley L, Warren RB, Griffiths CEM. Progress to date in advancing stratified medicine in psoriasis. Am J Clin Dermatol. 2020;21(5):619–26.

    Article  Google Scholar 

  4. Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302.

    Article  CAS  Google Scholar 

  5. Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol. 2018;178(5):1064–71.

    Article  CAS  Google Scholar 

  6. Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–45.

    Article  Google Scholar 

  7. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–92.

    Article  CAS  Google Scholar 

  8. Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Database Syst Rev. 2014;(10):MR000035.

  9. Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol. 2021;157(1):66–73.

    Article  Google Scholar 

  10. Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177(5):1410–21.

    Article  CAS  Google Scholar 

  11. Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9.e9.

    Article  CAS  Google Scholar 

  12. Shalom G, Cohen AD, Feldhamer I, Comaneshter D, Freud T, Pavlovsky L. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J Eur Acad Dermatol Venereol. 2020;34(7):1524–8.

    Article  CAS  Google Scholar 

  13. Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.

    Article  CAS  Google Scholar 

  14. Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–64.

    Article  Google Scholar 

  15. Observational studies in a learning health system: workshop summary. National Academies Press, Washington, DC; 2013.

Download references

Author information

Authors and Affiliations

  1. Laboratory of Investigative Dermatology, The Rockefeller University, 1230 York Ave, New York, NY, 10065, USA

    Yael Renert-Yuval & James G. Krueger

  2. Center for Clinical and Translational Science, The Rockefeller University, New York, NY, USA

    Jonathan N. Tobin

  3. Clinical Directors Network (CDN), New York, NY, USA

    Jonathan N. Tobin

Authors
  1. Yael Renert-Yuval
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James G. Krueger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan N. Tobin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yael Renert-Yuval.

Ethics declarations

Funding

Yael Renert-Yuval, James G. Krueger, and Jonathan N. Tobin were supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health Clinical and Translational Science Award program through The Rockefeller University, Grant no. UL1TR001866.

Conflict of interest

James G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. Jonathan N. Tobin has received research support (grants paid to his institution) and/or personal fees from National Institutes of Health, Agency for Healthcare Research and Quality, Patient-Centered Outcomes Research Institute, Bio-Ascend LLC, Regional Cancer Care Associates, Washington University in St. Louis, Astra Zeneca, Merck, Bristol Myers Squibb, Purdue Pharma, and Syneos. Yael Renert-Yuval has no conflicts of interest that are directly relevant to the content of this letter.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Authors’ contributions

Not applicable.

Additional information

This comment refers to the article available at: https://doi.org/10.1007/s40257-021-00598-4

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Renert-Yuval, Y., Krueger, J.G. & Tobin, J.N. The Busy Arena of Psoriasis Treatments: Improving the Clinician’s Ability to Make the Right Therapeutic Choice. Am J Clin Dermatol 22, 731–733 (2021). https://doi.org/10.1007/s40257-021-00617-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-021-00617-4

Search

Navigation